Flexural Eruption Associated With Arsenic Trioxide Therapy in a Patient With Acute Promyelocytic Leukemia

Teran, Victor A.; Wilson, Barbara B.; Guffey, Darren

doi:10.1001/jamadermatol.2018.5258

Cited by 5 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Arsenic trioxide has been used alone and in combination as drug therapy for acute promyelocytic leukemia. 2,3 In addition, there has been constant progress in applying arsenic trioxide treatment for solid tumors, including HCC. 4–7 As 2 O 3 can promote the differentiation of surviving cancer cells.…”

Section: Introductionmentioning

confidence: 99%

Local delivery of arsenic trioxide nanoparticles for hepatocellular carcinoma treatment

Ding

et al. 2019

Sig Transduct Target Ther

106

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a malignancy with a poor prognosis. Surgery combined with chemotherapy has been recommended as a curative regimen for HCC. Nevertheless, the anticancer mechanisms of chemicals in hepatocellular carcinoma remain unclear. Pyroptosis is a type of programmed necrosis, and its mechanism in hepatocellular carcinoma is poorly understood. The efficacy and mechanism of arsenic trioxide nanoparticles in the treatment of HCC were explored in this research. Arsenic trioxide alone and arsenic trioxide nanoparticles were conveniently administered to mice intratumorally using a needle. Compared with As2O3, As2O3 nanoparticles (As2O3-NPs) showed better inhibition, promoted greater LDH release, and induced cell morphology indicative of pyroptosis in vitro. Compared with the free drug, As2O3-NPs increased GSDME-N expression and decreased Dnmt3a, Dnmt3b, and Dnmt1 expression in Huh7 cells. In vivo, As2O3-NPs induced a significant decrease in the expression of Dnmt3a, Dnmt3b and Dnmt1, but significantly upregulated the expression of GSDME-N (gasdermin E (GSDME) was originally found to be related to deafness; recently, it has been defined as a gasdermin family member associated with pyroptosis). As2O3-NPs inhibited tumor growth more strongly than As2O3 or control, a finding likely attributed to the downregulation of PCNA and DNMT-related proteins and the upregulation of GSDME-N.

show abstract

Section: Introductionmentioning

confidence: 99%

Local delivery of arsenic trioxide nanoparticles for hepatocellular carcinoma treatment

Ding

et al. 2019

Sig Transduct Target Ther

106

View full text Add to dashboard Cite

show abstract

“…ATRA can effectively induce the differentiation of tumor initiation cells and enhance the cytotoxicity of cisplatin, thus enhancing the chemotherapeutic effect of cisplatin on HCC ( 71 ). As2O3, like ATRA, has been used in the clinical treatment of acute promyelocytic leukemia ( 72 ). As2O3 can restrict the growth of hepatoma cells, down-regulate the anti-apoptotic protein Bcl-xL, and up-regulate the expression of Notch, leading to apoptosis ( 73 ).…”

Section: Treatment Statusmentioning

confidence: 99%

Hepatocellular Carcinoma Differentiation: Research Progress in Mechanism and Treatment

Song

Zhou

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver. Although progress has been made in diagnosis and treatment, morbidity and mortality continue to rise. Chronic liver disease and liver cirrhosis are still the most important risk factors for liver cancer. Although there are many treatments, it can only be cured by orthotopic liver transplantation (OLT) or surgical resection. And the worse the degree of differentiation, the worse the prognosis of patients with liver cancer. Then it can be considered that restoring a better state of differentiation may improve the prognosis. The differentiation treatment of liver cancer is to reverse the dedifferentiation process of hepatocytes to liver cancer cells by means of drugs, improve the differentiation state of the tumor, and restore the normal liver characteristics, so as to improve the prognosis. Understanding the mechanism of dedifferentiation of liver cancer can provide ideas for drug design. Liver enrichment of transcription factors, imbalance of signal pathway and changes of tumor microenvironment can promote the occurrence and development of liver cancer, and restoring its normal level can inhibit the malignant behavior of tumor. At present, some drugs have been proved to be effective, but more clinical data are needed to support the effectiveness and reliability of drugs. The differentiation treatment of liver cancer is expected to become an important part of the treatment of liver cancer in the future.

show abstract

“…Arsenic is a potential candidate for adjuvant therapies [ 2 ] of advanced HCC with a long history of being used as a pigment and poison for the human body and tissue. Currently, arsenic trioxide (ATO) was highly recommended for leukemia and serves as the first-line treatment for acute promyelocytic leukemia (APL) [ 3 ]. Differing from the promising therapeutic effects in APL, the outcome of HCC patients treated with ATO is unsatisfactory.…”

Section: Introductionmentioning

confidence: 99%

Arsenic Trioxide Cooperate Cryptotanshinone Exerts Antitumor Effect by Medicating Macrophage Polarization through Glycolysis

Jiang

Huang

et al. 2022

Journal of Immunology Research

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is an often-fatal malignant tumor with high lethality. Despite advances and significant efficacy in monotherapy, cancer therapy continues to pose several challenges. Novel combination regimens are an emerging strategy for anti-HCC and have demonstrated to be effective. Here, we propose a potential combination for HCC treatment named arsenic trioxide cooperate cryptotanshinone (ACCS). A remarkable synergistic therapeutic effect has been achieved compared with drugs alone in both in vivo and in vitro experiments. Mechanism study indicated that ACCS exerts its therapeutic actions by regulating macrophage-related immunity and glycolysis. ACCS potentiates the polarization of M1 macrophages and elevates the proportion of M1/M2 to remodel tumor immunity. Further molecular mechanism study revealed that ACCS intensifies the glucose utilization and glycolysis in the macrophage by increasing the phosphorylation of AMPK to activating the AMPK singling pathway. In conclusion, ACCS is a highly potential combination regimen for HCC treatment. The therapeutic potential of ACCS as a candidate option for anticancer drugs in restoring the balance of immunity and metabolism deserves further investigation.

show abstract

Flexural Eruption Associated With Arsenic Trioxide Therapy in a Patient With Acute Promyelocytic Leukemia

Abstract: We thank the patient's parent for granting permission to publish this information.

Cited by 5 publications

References 8 publications

Local delivery of arsenic trioxide nanoparticles for hepatocellular carcinoma treatment

Local delivery of arsenic trioxide nanoparticles for hepatocellular carcinoma treatment

Hepatocellular Carcinoma Differentiation: Research Progress in Mechanism and Treatment

Arsenic Trioxide Cooperate Cryptotanshinone Exerts Antitumor Effect by Medicating Macrophage Polarization through Glycolysis

Contact Info

Product

Resources

About